Ombitasvir/paritaprevir/ritonavir
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Viekira Pak?
Summarize this article for a 10 year old
Ombitasvir/paritaprevir/ritonavir, sold under the brand name Technivie among others, is a medication used to treat hepatitis C.[2] It is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir.[2] Specifically it is used together with dasabuvir or ribavirin for cases caused by hepatitis C virus genotype 1 or 4.[2][3] Cure rates are around 95%.[3] It is taken by mouth.[2]
Combination of | |
---|---|
Ombitasvir | Antiviral (NS5A inhibitor) |
Paritaprevir | Antiviral (NS3 inhibitor) |
Ritonavir | PK enhancer (CYP3A4, CYP2D6 inhibitor) |
Clinical data | |
Trade names | Viekira Pak (with dasabuvir), Technivie, Viekirax, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615036 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem SID | |
ChemSpider |
|
KEGG |
|
ChEBI | |
(verify) |
Combination of | |
---|---|
Dasabuvir | Antiviral |
Ombitasvir | Antiviral (NS5A inhibitor) |
Paritaprevir | Antiviral (NS3 inhibitor) |
Ritonavir | PK enhancer (CYP3A4, CYP2D6 inhibitor) |
Clinical data | |
Trade names | Viekira Pak, Viekira XR, Holkira Pak, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614057 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
PubChem CID | |
ChemSpider |
|
KEGG | |
ChEBI |
It is generally well tolerated.[4] Common side effects include nausea, itchiness, rash, and trouble sleeping.[2] Other side effects include allergic reactions and reactivation of hepatitis B among those previously infected.[2] Use is not recommended in those with significant liver problems.[2] While there is no evidence of harm with use during pregnancy, this use has not been well studied.[2] Each of the medications works by a different mechanism.[3] The ritonavir is present to decrease the breakdown of paritaprevir.[2]
Ombitasvir/paritaprevir/ritonavir with dasabuvir was approved for medical use in the United States in 2014, and without dasabuvir in 2015.[5][6] It is on the World Health Organization's List of Essential Medicines.[7]